Shanghai: Accelerating to a world-class biomedical industry highland
2021-11-29
Quietly, biomedicine is an important pillar of Shanghai's strategic emerging industries. At present, together with artificial intelligence and integrated circuits, it has become a leading industry for Shanghai to participate in global cooperation and competition on behalf of the country.
According to the latest data, as of August this year, the total output value of Shanghai biomedical manufacturing industry was 104.115 billion yuan, a comparable increase of 15.6%; The new investment was 8.44 billion yuan, a year-on-year increase of 85.6%. At the same time, a "1 + 5 + X" industrial development layout has been formed with Zhangjiang as the core, supported by five characteristic parks such as Lingang New film area and supplemented by other characteristic bases, and the linkage development pattern of "Zhangjiang R & D + made in Shanghai" has been continuously optimized.
From October 11th, the first Shanghai International Biomedical Industry Week will kick off. Top scientists, top investors and CEOs of many domestic and foreign biomedical companies from all over the world will gather on the banks of the Huangpu River to jointly provide advice and suggestions for the development of Shanghai's biomedical industry. . Throughout the development of the national biomedical industry, Shanghai is the first region to start. With a sound and developed industrial system, rich innovation elements, a high degree of internationalization and leading R & D and innovation ability in the country, Shanghai has initially formed a good industrial innovation ecology.
Especially in 2020, the scale of Shanghai's biomedical industry will exceed 600 billion yuan, of which the total industrial output value will exceed 140 billion yuan. In the first half of this year, the industrial scale exceeded 350 billion yuan, a significant increase of 22.8% year-on-year. At the same time, in less than two years, a number of major technological achievements and products have emerged to fill the gaps at home and abroad. For example, in major frontier research, breakthroughs have been made in a number of original innovative achievements, such as the world's first cloned monkey model of rhythm disorder disease and the first artificial single chromosome eukaryotic cell. The data show that in 2020, the city's biomedical enterprises won 177 drug approvals from the State Food and drug administration, including 18 production approvals; 26 national key R & D projects have been approved, and a number of major projects such as wireless cardiac pacemakers and domestic particle therapy devices have entered the national special projects; The 5mhu medical ball tube, the core component of CT, was made in China. The world's first 75cm super large aperture 3.0T magnetic resonance equipment was born in Shanghai.
According to Zhang Qing, deputy director of the Shanghai Municipal Drug Administration, Shanghai has newly approved 6 domestically produced innovative drugs of Class I this year, accounting for about 1/4 of the country’s total, a record high over the years; Nine new products have entered the special approval channel for national innovative medical devices, accounting for about 1 / 5 of the country. In addition, Shanghai has established 6 national-level and 17 municipal-level clinical medical research centers, and has gathered a group of leading domestic research institutes in the fields of life sciences and pharmacy, and 16 superior clinical disciplines such as cardiovascular disease and oncology nationwide ranked in the top three. It can be said that Shanghai's biomedical innovation strategy capability has been in the leading position in the country. Internationalization is also a distinctive feature of Shanghai Biomedicine. At present, foreign-funded biopharmaceutical companies account for about 60% of the city. 18 of the top 20 global pharmaceutical companies and 17 of the top 20 medical devices have settled in Shanghai, setting up China headquarters or R&D centers or production bases. The Shanghai international biomedical industry provides a bridge for the local biomedical industry to integrate with the world. To converge energy, to promote production. Shanghai will grasp the general direction and trend of the booming and prosperous global bio-economy, and accelerate the cultivation and growth of biomedical industry clusters.
Accelerate the transformation of innovation achievements, lead by "Zhangjiang R&D + Shanghai Manufacturing", relying on the "1+5+X" industrial space carrier, strengthen cross-regional linkage and overall planning, encourage various parks to innovate and coordinate models, linkage and coordinated development, and effectively improve Shanghai Carrying capacity of biomedical projects. Shanghai's goal is to strive to reach 1.2 trillion yuan in the city's biomedicine industry by 2025, of which the output value of the manufacturing industry will reach 280 billion yuan, making the biomedical industry "Shanghai Highland" more and more attractive. In 2022 or a long time in the future, Shanghai IVEN will also invest more efforts in biopharmaceuticals, joining the research and development and production of vaccines and other machines, and aspire to become a leading company in the development of the biological industry. Let us look forward it together !
NEWS
